Daily low-dose Tacrolimus (TAC) is a save and efficient immunosuppressive regimen during triple drug therapy post liver transplant

Aims: Graft loss from hepatitis C virus (HCV) recurrence remains a major problem after liver transplantation (LT), and the response to standard therapy is poor. Triple therapy opens a new perspective for better graft and patient survival but severe drug interactions are a potential limitation in LT patients. We report our experience using low-dose tacrolimus (TAC) on a daily base in patients who undergo HCV triple therapy due to post LT recurrence of HCV infection. Methods: 16 patients with HCV genotype (GT) 1 recurrence after liver transplant were treated with telaprevir (TVR), pegylated interferon-alpha (PEG)…